DUBLIN--(BUSINESS WIRE)--The "Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report" report has been added to ResearchAndMarkets.com's offering.

Since the discovery of induced pluripotent stem cells (iPSCs) a large and thriving research product market has grown into existence, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number.

Therapeutic applications of iPSCs have surged in recent years. 2013 was a landmark year in Japan because it saw the first cellular therapy involving the transplant of iPSCs into humans initiated at the RIKEN Center in Kobe, Japan. Led by Masayo Takahashi of the RIKEN Center for Developmental Biology (CDB), it investigated the safety of iPSC-derived cell sheets in patients with macular degeneration.

In another world-first, Cynata Therapeutics received approval in 2016 to launch the world's first formal clinical trial of an allogeneic iPSC-derived cell product (CYP-001) for the treatment of GvHD. Riding the momentum within the CAR-T field, Fate Therapeutics is developing FT819, its off-the-shelf iPSC-derived CAR-T cell product candidate. Numerous physician-led studies using iPSCs are also underway in Japan, a leading country for basic and applied iPSC applications.

Key Topics Covered:

1. Report Overview

2. Introduction

3. History of Induced Pluripotent Stem Cells (IPSCS)

3.1 First iPSC generation from Mouse Fibroblasts, 2006

3.2 First Human iPSC Generation, 2007

3.3 Creation of CiRA, 2010

3.4 First High-Throughput screening using iPSCs, 2012

3.5 First iPSCs Clinical Trial Approved in Japan, 2013

3.6 The First iPSC-RPE Cell Sheet Transplantation for AMD, 2014

3.7 EBiSC Founded, 2014

3.8 First Clinical Trial using Allogeneic iPSCs for AMD, 2017

3.9 Clinical Trials for Parkinson's disease using Allogeneic iPSCs, 2018

3.10 Commercial iPSC Plant SMaRT Established, 2018

3.11 First iPSC Therapy Center in Japan, 2019

4. Research Publications on IPSCS

4.1 Categories of Research Publications

4.2 Percent Share of Published Articles by Disease Type

4.3 Number of Articles by Country

5. IPSCS: Patent Landscape

5.1 Timeline and Status of Patents

5.2 Patent Filing Destinations

5.3 Patent Application Trends iPSC Preparation Technologies

5.4 Patent Application Trends in iPSC Differentiation Technologies

5.5 Patent Application Trends in Disease-Specific Cell Technologies

6. Clinical Trials Involving IPSCS

6.1 Current Clinical Trials Landscape

6.1.1 Clinical Trials Involving iPSCs by Major Diseases

6.1.2 Clinical Trials Involving iPSCs by Country

7. Funding for IPSC

7.1 Value of NIH Funding for iPSCs

7.1.1 NHI's Intended Funding Through its Component Organizations in 2020

7.1.2 NIH Funding for Select Universities for iPSC Studies

7.2 CIRM Funding for iPSCs

8. Generation of Induced Pluripotent Stem Cells: An Overview

8.1 Reprogramming Factors

8.2 Overview of Four Key Methods of Gene Delivery

8.3 Comparative Effectiveness of Different Vector Types

8.4 Genome Editing Technologies in iPSCs Generation

9. Human IPSC Banking

9.1 Cell Sources for iPSCs Banking

9.2 Reprogramming methods used in iPSC Banking

9.3 Workflow in iPSC Banks

9.4 Existing iPSC Banks

10. Biomedical Applications of IPSCS

10.1 iPSCs in Basic Research

10.2 iPSCs in Drug Discovery

10.3 iPSCs in Toxicology Studies

10.4 iPSCs in Disease Modeling

10.5 iPSCs in Cell-Based Therapies

11. Other Novel Applications of IPSCS

11.1 iPSCs in Tissue Engineering

11.2 iPSCs in Animal Conservation

11.3 iPSCs and Cultured Meat

12. Deals in the IPSCS Sector

12.1 $250 million Raised by Century Therapeutics

12.2 BlueRock Therapeutics Launched with $225 Million

12.3 Collaboration between Allogene Therapeutics and Notch Therapeutics

12.4 Acquisition of Semma Therapeutics by Vertex Therapeutics

12.5 Evotec's Extended Collaboration with BMS

12.6 Licensing Agreement between Allele Biotechnology and Astellas Pharma

12.7 Co-development Agreement between Allele & SCM Lifesciences

12.8 Fate Therapeutics Signs $100 Million Deal with Janssen

12.9 Allele's Deal with Alpine Biotherapeutics

12.10 Editas and BlueRock's Development Agreement

13. Market Overview

13.1 Global Market for iPSCs by Geography

13.2 Global Market for iPSCs by Technology

13.3 Global Market for iPSCs by Biomedical Application

13.4 Global Market for iPSCs by Cell Types

13.5 Market Drivers

13.6 Market Restraints

13.6.1 Economic Issues

13.6.2 Genomic Instability

13.6.3 Immunogenicity

13.6.4 Biobanking of iPSCs

14. Company Profiles

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/t6jcqp

More:
2020 Insights on the Worldwide Induced Pluripotent Stem Cell Industry - ResearchAndMarkets.com - Business Wire